Piroxicam

Piroxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties.^1,2 It inhibits production of thromboxane B₂ (TXB₂; Item No. 19030) from arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) in HEL human erythroleukemic cells (IC₅₀ = 0.45 µM), which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F_1α (PGF_1α; Item No. 15010) from arachidonic acid in Mono-Mac-6 cells (IC₅₀ = 0.77 µM), which endogenously express COX-2.² Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC₅₀ values of 240 and ~470 µM, respectively. It reduces carrageenan-induced paw edema in rats when administered at doses of 1, 2.5, and 5 mg/kg.³ Formulations containing piroxicam have been used in the treatment of pain and inflammation associated with osteoarthritis and rheumatoid arthritis.

WARNING This product is not for human or veterinary use.

1. Pairet, M., van Ryn, J., Schierok, H., et al. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer. Inflamm. Res. 47(6), 270-276 (1998).

2. Berg, J., Fellier, H., Christoph, T., et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm. Res. 48(7), 369-379 (1999).

3. Buritova, J., Honore, P., Chapman, V., et al. Carrageenan oedema and spinal Fos-LI neurones are reduced by piroxicam in the rat. Neuroreport 6(10), 1385-1388 (1995).